Company Interview / Aussie MedTech breathing in advancements

Darryl Davies from inhaleRx (ASX: IRX) discusses their recent $38.5 million fundraise to propel clinical trials for their inhaler, aiming to address pain management and panic disorder. This major milestone supports advancing to phase three trials.

Darryl outlines the innovative inhaler 211, targeting breakthrough cancer pain, which combines familiar asthma technology as a drug delivery device. Promising results from phase one trials in Melbourne set a strong foundation for its future development.

The market potential for their panic disorder candidate, 616A, is also significant, particularly after a 25% prevalence increase post-COVID-19. With no FDA-approved drug for this indication, Inhale IRX sees a unique opportunity for 616A.